{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:00:42Z","timestamp":1787032842977,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,30]]},"DOI":"10.7759\/cureus.49763","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T02:33:33Z","timestamp":1701398013000},"source":"Crossref","is-referenced-by-count":3,"title":["Retrospective Evaluation of a Dexamethasone Sparing Antiemetic Regimen: An Antiemetic Prophylaxis Study on NEPA (Netupitant Plus Palonosetron) for Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients"],"prefix":"10.7759","author":[{"given":"Suhas","family":"Agre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhura","family":"Agre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubarakunnisa","family":"Tonse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitasha","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfiya","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta K","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun. 2021, 26:100278. 10.1016\/j.ctarc.2020.100278","journal-title":"Cancer Treat Res Commun"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000514891","article-title":"Quality of life effects of an oral fixed combination of netupitant and palonosetron in chemotherapy-induced nausea and vomiting prevention: real-world evidence in patients with breast cancer receiving anthracycline-cyclophosphamide-based chemotherapy","volume":"17","author":"Schilling J","year":"2022","unstructured":"Schilling J, Kurbacher CM, Hanusch C, et al.. Quality of life effects of an oral fixed combination of netupitant and palonosetron in chemotherapy-induced nausea and vomiting prevention: real-world evidence in patients with breast cancer receiving anthracycline-cyclophosphamide-based chemotherapy. Breast Care (Basel). 2022, 17:130-136. 10.1159\/000514891","journal-title":"Breast Care (Basel)"},{"key":"ref3","unstructured":"Nausea and vomiting related to cancer treatment (PDQ\u00ae)-Health professional version. (2023). Accessed. November 30, 2023: https:\/\/www.cancer.gov\/about-cancer\/treatment\/side-effects\/nausea\/nausea-hp-pdq#:~:text=Chemotherapy%2Dinduced%20N%26...."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10018-3","article-title":"Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant\/palonosetron) in the cisplatin setting: results from a randomized phase 3 study","volume":"22","author":"Celio L","year":"2022","unstructured":"Celio L, Cortinovis D, Cogoni AA, et al.. Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant\/palonosetron) in the cisplatin setting: results from a randomized phase 3 study. BMC Cancer. 2022, 22:915. 10.1186\/s12885-022-10018-3","journal-title":"BMC Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2017.1394549","article-title":"Dexamethasone exacerbates cytotoxic chemotherapy induced lethargy and weight loss in female tumor free mice","volume":"19","author":"Wong J","year":"2017","unstructured":"Wong J, Tran LT, Lynch KA, Wood LJ. Dexamethasone exacerbates cytotoxic chemotherapy induced lethargy and weight loss in female tumor free mice. Cancer Biol Ther. 2017, 19:87-96. 10.1080\/15384047.2017.1394549","journal-title":"Cancer Biol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13680","article-title":"Reconsidering dexamethasone for antiemesis when combining chemotherapy and immunotherapy","volume":"26","author":"Janowitz T","year":"2021","unstructured":"Janowitz T, Kleeman S, Vonderheide RH. Reconsidering dexamethasone for antiemesis when combining chemotherapy and immunotherapy. Oncologist. 2021, 26:269-273. 10.1002\/onco.13680","journal-title":"Oncologist"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1188\/18.CJON.E52-E63","article-title":"Fixed combination antiemetic: a literature review on prevention of chemotherapy-induced nausea and vomiting using netupitant\/palonosetron","volume":"22","author":"Clark-Snow RA","year":"2018","unstructured":"Clark-Snow RA, Vidall C, B\u00f6rjeson S, Jahn P. Fixed combination antiemetic: a literature review on prevention of chemotherapy-induced nausea and vomiting using netupitant\/palonosetron. Clin J Oncol Nurs. 2018, 22:52-63. 10.1188\/18.CJON.E52-E63","journal-title":"Clin J Oncol Nurs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.92","article-title":"Chemotherapy: NEPA-a single oral dose providing effective prevention of chemotherapy-induced nausea and vomiting","volume":"11","author":"Errico A","year":"2014","unstructured":"Errico A. Chemotherapy: NEPA-a single oral dose providing effective prevention of chemotherapy-induced nausea and vomiting. Nat Rev Clin Oncol. 2014, 11:377. 10.1038\/nrclinonc.2014.92","journal-title":"Nat Rev Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231173863","article-title":"A phase II trial of netupitant\/palonosetron for prevention of chemotherapy-induced nausea\/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation","author":"Bubalo JS","year":"2023","unstructured":"Bubalo JS, Radke JL, Bensch KG, Chen AI, Misra S, Maziarz RT. A phase II trial of netupitant\/palonosetron for prevention of chemotherapy-induced nausea\/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation. J Oncol Pharm Pract. 2023, 10781552231173863. 10.1177\/10781552231173863","journal-title":"J Oncol Pharm Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3123","article-title":"Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3\u2010day aprepitant regimen for prevention of chemotherapy\u2010induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study","volume":"9","author":"Chang J","year":"2020","unstructured":"Chang J, Chen G, Wang D, et al.. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3\u2010day aprepitant regimen for prevention of chemotherapy\u2010induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study. Cancer Med. 2020, 9:5134-5142. 10.1002\/cam4.3123","journal-title":"Cancer Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08342-1","article-title":"The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting","volume":"21","author":"Vaswani B","year":"2021","unstructured":"Vaswani B, Dattatreya PS, Bhagat S, Patil S, Barkate H. The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting. BMC Cancer. 2021, 21:601. 10.1186\/s12885-021-08342-1","journal-title":"BMC Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-28464-9","article-title":"Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)","volume":"13","author":"Celio L","year":"2023","unstructured":"Celio L, Cortinovis D, Cogoni AA, et al.. Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study). Sci Rep. 2023, 13:1257. 10.1038\/s41598-023-28464-9","journal-title":"Sci Rep"},{"key":"ref13","article-title":"Chemotherapy-induced nausea and vomiting: optimizing prevention and management","volume":"5","author":"Rao KV","year":"2012","unstructured":"Rao KV, Faso A. Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits. 2012, 5:232-240.","journal-title":"Am Health Drug Benefits"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02537-7","article-title":"Real-world treatment outcomes, healthcare resource use, and costs associated with antiemetics among cancer patients on cisplatin-based chemotherapy","volume":"40","author":"Navari RM","year":"2023","unstructured":"Navari RM, Nelson WW, Shoaib S, Singh R, Zhang W, Bailey WL. Real-world treatment outcomes, healthcare resource use, and costs associated with antiemetics among cancer patients on cisplatin-based chemotherapy. Adv Ther. 2023, 40:3217-3226. 10.1007\/s12325-023-02537-7","journal-title":"Adv Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2174\/1568009622666220513094352","article-title":"Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice","volume":"22","author":"Aapro M","year":"2022","unstructured":"Aapro M, Jordan K, Scott\u00e9 F, Celio L, Karthaus M, Roeland E. Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice. Curr Cancer Drug Targets. 2022, 22:806-824. 10.2174\/1568009622666220513094352","journal-title":"Curr Cancer Drug Targets"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0023","article-title":"Single-dose netupitant\/palonosetron\u00a0versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a\u00a0pooled analysis","volume":"17","author":"Navari RM","year":"2021","unstructured":"Navari RM, Binder G, Bonizzoni E, Clark-Snow R, Olivari S, Roeland EJ. Single-dose netupitant\/palonosetron\u00a0versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a\u00a0pooled analysis. Future Oncol. 2021, 17:3027-3035. 10.2217\/fon-2021-0023","journal-title":"Future Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx698","article-title":"A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)","volume":"29","author":"Zhang L","year":"2018","unstructured":"Zhang L, Lu S, Feng J, et al.. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018, 29:452-458. 10.1093\/annonc\/mdx698","journal-title":"Ann Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2809-3","article-title":"Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study","volume":"23","author":"Escobar Y","year":"2015","unstructured":"Escobar Y, Cajaraville G, Virizuela JA, et al.. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support Care Cancer. 2015, 23:2833-2840. 10.1007\/s00520-015-2809-3","journal-title":"Support Care Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/203293-retrospective-evaluation-of-a-dexamethasone-sparing-antiemetic-regimen-an-antiemetic-prophylaxis-study-on-nepa-netupitant-plus-palonosetron-for-preventing-chemotherapy-induced-nausea-and-vomiting-cinv-in-cancer-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T15:07:53Z","timestamp":1707491273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/203293-retrospective-evaluation-of-a-dexamethasone-sparing-antiemetic-regimen-an-antiemetic-prophylaxis-study-on-nepa-netupitant-plus-palonosetron-for-preventing-chemotherapy-induced-nausea-and-vomiting-cinv-in-cancer-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.49763","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}